At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 581 enrolled
Drug / intervention
0.15% azelastine hydrochloride +2 moredrug
Likely dose
0.15% azelastine hydrochloride 1644 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 in Patients With Perennial Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, and 1 other intervention for Perennial Allergic Rhinitis. Completed, enrolled 581 participants across 43 sites.
Detailed Summary
The purpose of this study is to determine if two allergy medications are more effective than placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionMay 2008
First PostedJul 2008
TodayJul 2026
First PostedJul 10, 2008
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.0 years ago
Interventions
0.15% azelastine hydrochloridedrug
0.15% azelastine hydrochloride 1644 mcg
0.1% azelastine hydrochloridedrug
0.1% azelastine hydrochloride 1096 mcg
Placebodrug
Placebo